TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32506135

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (3 g/d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sodium supplementation (3 g/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 35611615

Group type: EXPERIMENTAL
Intervention: 12-week combined aerobic-and neurocognitive-exercise (3 sessions per week for 60-min)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined aerobic and neurocognitive exercise intervention
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Physical activity levels
Number of subjects: 80
Study: 33586539

Group type: EXPERIMENTAL
Intervention: COVID-19 perception
Number of subjects: 376
Study: 32275191

Group type: EXPERIMENTAL
Intervention: Anakinra (Kineret) for 2 days
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Anakinra (Kineret) for 4 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 35073229

Group type: EXPERIMENTAL
Intervention: Experimental vignette methodology (four vignettes about alcohol misuse)
Number of subjects: 251
Study: 33858430

Group type: EXPERIMENTAL
Intervention: BPH group
Number of subjects: 107
Study: 32053816

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) performed 48 hours after treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: CECT at 1-month (reference standard)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: CEUS responders (48 h after treatment)
Number of subjects: 94
Study: 35896969

Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Exercise training programme (for both groups)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy and exercise training
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo and exercise training
Number of subjects: 75
Study: 36201834

Group type: EXPERIMENTAL
Intervention: Friend Present condition
Number of subjects: 100

Group type: COMPARATOR
Intervention: Friend Absent condition
Number of subjects: 100
Study: 33763652

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri supplementation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 32101262

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (target <120 mm Hg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard blood pressure control (target <140 mm Hg)
Number of subjects: 9361
Study: 34275501

Group type: EXPERIMENTAL
Intervention: Daily oral vitamin D3 drops (3‐12 months: 2000 IU; >12 months‐5y: 4000 IU; n=33) for 12 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Single oral depot dose of vitamin D3 granules (3‐12 months: 60,000 IU; >12 months‐5y: 150,000 IU; n=33) for 12 weeks
Number of subjects: 66
Study: 32650076

Group type: EXPERIMENTAL
Intervention: Dynamic Isotonic Manipulation Examination (DIME) testing
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: DIME strength ≤86.0 N
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Pain at ≤90° on unopposed active abduction in the coronal plane
Number of subjects: 171
Study: 35007624

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneous every 4 weeks
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo plus standard of care
Number of subjects: 407
Study: 36099670

Group type: EXPERIMENTAL
Intervention: docetaxel plus AAP
Number of subjects: 148

Group type: COMPARATOR
Intervention: docetaxel plus prednisone
Number of subjects: 148
Study: 33821797

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 32460885

Group type: EXPERIMENTAL
Intervention: NHS Speech and Language Therapy (SLT)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Treatment (LSVT LOUD®)
Number of subjects: 546

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: NHS SLT
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: LSVT LOUD®
Number of subjects: 546
Study: 34846593

Group type: EXPERIMENTAL
Intervention: Experimental group (E) - chest drain removal at 5 ml/kg daily output
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (C) - chest drain removal at less than 250 ml/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 33225492

Group type: EXPERIMENTAL
Intervention: Augmenting with aripiprazole (A-ARI)
Number of subjects: 1522

Group type: COMPARATOR
Intervention: Switching to bupropion-SR (S-BUP)
Number of subjects: 1522

Group type: COMPARATOR
Intervention: Combining with bupropion-SR (C-BUP)
Number of subjects: 1522

Group type: EXPERIMENTAL
Intervention: Continuation treatment (all groups)
Number of subjects: 1522
Study: 36471311

Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach (SAIA) for integrating HIV testing into FP services
Number of subjects: 36086

Group type: EXPERIMENTAL
Intervention: Ministry of Health-supported intervention scenario
Number of subjects: 36086
Study: 33271536

Group type: EXPERIMENTAL
Intervention: Active learning program (90-min sessions weekly for 24 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (90-min didactic teaching method)
Number of subjects: 60
Study: 35045362

Group type: EXPERIMENTAL
Intervention: V591 (low dose, 1 × 10^5 TCID50)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: V591 (high dose, 1 × 10^6 TCID50)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: V591 (two injections)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: V591 (low dose, two injections)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: V591 (high dose, two injections)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: V591
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pre-existing anti-measles immunity
Number of subjects: 90
Study: 32704178

Group type: EXPERIMENTAL
Intervention: BMI and adipose tissue content assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-invasive diagnostic methods for mapping foot load distribution
Number of subjects: 0
Study: 36420365

Group type: EXPERIMENTAL
Intervention: Functional and Kinetic Treatment with Rehabilitation (FAKTR) combined with cryotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 40
Study: 32247315

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride (BH) spray
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control (normal saline lubrication without BH spray)
Number of subjects: 142
Study: 33107977

Group type: EXPERIMENTAL
Intervention: Tissue level implants with a partially smooth collar in thin phenotype group (n=13)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tissue level implants with a partially smooth collar in thick phenotype group (n=13)
Number of subjects: 30
Study: 36195338

Group type: EXPERIMENTAL
Intervention: LYS006 5 mg once daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: LYS006 15 mg once daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: LYS006 20-80 mg twice a day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: LYS006 (various doses)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: LYS006
Number of subjects: 9
Study: 34751928

Group type: EXPERIMENTAL
Intervention: Ulotaront (TAAR1 agonist)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Lurasidone (Dopamine D2 receptor-based antipsychotic)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Quetiapine (Dopamine D2 receptor-based antipsychotic)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Olanzapine (Dopamine D2 receptor-based antipsychotic)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 32844196

Group type: EXPERIMENTAL
Intervention: Levodopa monotherapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Levodopa treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Levodopa therapy
Number of subjects: 30
Study: 35317736

Group type: EXPERIMENTAL
Intervention: Action Observation + Virtual Reality (AO + VR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control treatment (Observation of naturalistic scenes + Virtual Reality) (CO + VR)
Number of subjects: 0
Study: 34479958

Group type: EXPERIMENTAL
Intervention: Recombinant human parathyroid hormone (1-84)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 34905513

Group type: EXPERIMENTAL
Intervention: Ob-NFG-NGT
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ob-NFG-IGT
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ob-IFG-IGT
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ob-T2D
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Insulin clearance
Number of subjects: 5
Study: 35041000

Group type: EXPERIMENTAL
Intervention: Individualized multimodality imaging-guided LV lead placement
Number of subjects: 182

Group type: COMPARATOR
Intervention: Routine fluoroscopic approach (Control)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: IED ≥100 ms
Number of subjects: 182
Study: 32054536

Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (35 mg/kg) alongside standard TB treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose rifampicin alongside standard TB treatment
Number of subjects: 0
Study: 35981598

Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 51

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 51
Study: 34105866

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 300 mg capsule twice daily for 3 months
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 92
Study: 32873323

Group type: EXPERIMENTAL
Intervention: Self-management intervention involving brief motivation/support by practice nurses
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care (healthy lifestyle leaflet)
Number of subjects: 28
Study: 36255560

Group type: EXPERIMENTAL
Intervention: Proxy 1 perspective
Number of subjects: 402

Group type: COMPARATOR
Intervention: Proxy 2 (substitute) perspective
Number of subjects: 402
Study: 33185376

Group type: COMPARATOR
Intervention: 30 mL 0.5% bupivacaine at 23°C
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 30 mL 0.5% bupivacaine warmed to 37°C
Number of subjects: 90
Study: 35819542

Group type: EXPERIMENTAL
Intervention: National Career Coach Program (NCCP)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Local Community Resources (LCR)
Number of subjects: 208
Study: 34846050

Group type: EXPERIMENTAL
Intervention: Closed kinematic chain exercises with eccentric and strength exercises
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study: 35803088

Group type: EXPERIMENTAL
Intervention: 600mg lavender flowers capsules, taken three times daily for 60 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: 600mg cornstarch capsules, taken three times daily for 60 days
Number of subjects: 48
Study: 34347865

Group type: EXPERIMENTAL
Intervention: Learn to Quit digital therapeutic
Number of subjects: 62

Group type: COMPARATOR
Intervention: NCI QuitGuide digital therapeutic
Number of subjects: 62
Study: 34724246

Group type: EXPERIMENTAL
Intervention: Personal Comfort System (PCS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no PCS)
Number of subjects: 18
Study: 33929284

Group type: EXPERIMENTAL
Intervention: Meniscal repair
Number of subjects: 150

Group type: COMPARATOR
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 150
Study: 34396615

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study: 32357926

Group type: EXPERIMENTAL
Intervention: EMPOWER intervention (7-week partnership-based and needs-tailored SMS intervention via telephone counseling)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: EMPOWER intervention
Number of subjects: 94

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 94
Study: 35029869

Group type: EXPERIMENTAL
Intervention: Early NMBA
Number of subjects: 1182

Group type: COMPARATOR
Intervention: No early NMBA
Number of subjects: 1182
Study: 32697197

Group type: EXPERIMENTAL
Intervention: Web-based intervention with health professional support to increase nebulizer adherence, including electronic monitoring and tailored website support.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Web-based intervention with health professional support to increase nebulizer adherence, tailored to individuals.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Modified intervention delivered through an app accessed via mobile phones.
Number of subjects: 14
Study: 36384398

Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver combined with controlled low central venous pressure (Group 20)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (Group 15)
Number of subjects: 151
Study: 34082176

Group type: EXPERIMENTAL
Intervention: 0.15% dietary Cl
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 0.21% dietary Cl
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 0.21% and 0.15% dietary Cl
Number of subjects: 360

Group type: COMPARATOR
Intervention: Na2SO4 and NaHCO3
Number of subjects: 360
Study: 32773737

Group type: COMPARATOR
Intervention: General anesthesia (GA) and postoperative intravenous analgesia (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) and postoperative epidural analgesia (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) combined with thoracic epidural anesthesia (TEA) and postoperative intravenous analgesia (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) combined with TEA and postoperative epidural analgesia (Group D)
Number of subjects: 0
Study: 34128083

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg bid)
Number of subjects: 5022

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5022

Group type: EXPERIMENTAL
Intervention: New-onset AF
Number of subjects: 5022
Study: 36368677

Group type: EXPERIMENTAL
Intervention: Isomyosamine 150 mg, 300 mg, 450 mg (single daily doses for 3 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isomyosamine 600 mg (multiple daily doses for 6 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isomyosamine (various doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isomyosamine 300 mg to 600 mg (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isomyosamine 600 mg (once daily for 5 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isomyosamine (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isomyosamine (elimination pathway)
Number of subjects: 0
Study: 33958552

Group type: EXPERIMENTAL
Intervention: Intervention Group 2 (ICUs 3 and 4; educational intervention with no monitoring visits)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (ICU 5; receiving no intervention)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Intervention Group 1 (ICUs 1 and 2; full intervention with monitoring visits)
Number of subjects: 117
Study: 35954509

Group type: EXPERIMENTAL
Intervention: General Anesthesia
Number of subjects: 72

Group type: COMPARATOR
Intervention: Brachial Plexus Block (BPB)
Number of subjects: 72
Study: 33491389

Group type: EXPERIMENTAL
Intervention: PerioTabs (NitrAdine-based gingiva brushing solution) for 10 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Any toothpaste (control group)
Number of subjects: 49
Study: 32079835

Group type: EXPERIMENTAL
Intervention: Cosmetic tattoos (reported by 17% of cases and 26% of controls)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Tattoo colors (specifically yellow and green)
Number of subjects: 369
Study: 35152314

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram model based on FS-T1WI and FS-T2WI sequences
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiomics model based on FS-T1WI and FS-T2WI sequences
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiomics model in training group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiomics model in test group
Number of subjects: 100
Study: 34006044

Group type: EXPERIMENTAL
Intervention: Point-of-care procalcitonin (PCT) test with standard sepsis parameter monitoring
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard monitoring only (C-reactive protein, total white count, temperature, tracheal aspirate culture)
Number of subjects: 100
Study: 35788146

Group type: EXPERIMENTAL
Intervention: Laser radiation (diode laser 808 nm)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 38
Study: 33439864

Group type: EXPERIMENTAL
Intervention: Explicit condition (children told the sorting rules)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Implicit condition (children given feedback to formulate the rules)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Explicit condition
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Exploratory analyses
Number of subjects: 137
Study: 35076302

Group type: EXPERIMENTAL
Intervention: Pavlik harness treatment
Number of subjects: 104

Group type: COMPARATOR
Intervention: Active observation
Number of subjects: 104
Study: 32902207

Group type: EXPERIMENTAL
Intervention: 12 weeks exercise program (resistance training, balance exercise, aerobic exercise)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 12 weeks exercise program
Number of subjects: 96
Study: 35377947

Group type: EXPERIMENTAL
Intervention: ibrutinib 420 mg once daily until disease progression/unacceptable toxicity (n = 136)
Number of subjects: 269

Group type: COMPARATOR
Intervention: chlorambucil 0.5-0.8 mg/kg ≤12 cycles (n = 133)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: ibrutinib
Number of subjects: 269
Study: 33991471

Group type: EXPERIMENTAL
Intervention: RE bout with WBV
Number of subjects: 20

Group type: COMPARATOR
Intervention: RE bout
Number of subjects: 20
Study: 32558199

Group type: EXPERIMENTAL
Intervention: Belatacept maintenance therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group with rabbit antithymocyte globulin (rATG) induction, rapid steroid taper, and maintenance mycophenolate and tacrolimus
Number of subjects: 69
Study: 36328822

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study: 33894947

Group type: EXPERIMENTAL
Intervention: Supported self-management through low-intensity psychological intervention
Number of subjects: 30
Study: 32680912

Group type: EXPERIMENTAL
Intervention: Improved biomass stoves vented with a chimney (Trial 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vented biomass stoves (Trial 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liquid petroleum gas (LPG) stoves (Trial 2)
Number of subjects: 0
Study: 34501680

Group type: EXPERIMENTAL
Intervention: Brief multimedia animated video about ACL injury and prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commonly accessed, text-based web resource about ACL injury and prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief multimedia video about concussions
Number of subjects: 0
Study: 33253497

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy
Number of subjects: 820

Group type: COMPARATOR
Intervention: Tocilizumab (TCZ) combined with methotrexate (TCZ+MTX)
Number of subjects: 820
Study: 36251465

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 13026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study: 32891161

Group type: EXPERIMENTAL
Intervention: Management of temporary suspension in clinical trials
Number of subjects: 0
Study: 35101098

Group type: EXPERIMENTAL
Intervention: Continuous infusion of rocuronium bromide for 48 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 48 hours
Number of subjects: 0
Study: 32809900

Group type: EXPERIMENTAL
Intervention: Viewing painful images
Number of subjects: 21

Group type: COMPARATOR
Intervention: Viewing pleasant images
Number of subjects: 21

Group type: COMPARATOR
Intervention: Viewing neutral images
Number of subjects: 21
Study: 35379247

Group type: EXPERIMENTAL
Intervention: Digital platform and structured telephone support
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Digital platform
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Digital platform direct messaging
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Direct-dial telephone contact
Number of subjects: 86
Study: 32152018

Group type: EXPERIMENTAL
Intervention: Fasting Algorithm for Singaporeans with Type 2 Diabetes (FAST)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual care without FAST
Number of subjects: 97
Study: 33960508

Group type: EXPERIMENTAL
Intervention: No-touch (NT) technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional (CON) technique
Number of subjects: 100
Study: 35303932

Group type: EXPERIMENTAL
Intervention: New membrane obturator prosthesis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional rigid obturator prosthesis
Number of subjects: 14
Study: 32809899

Group type: EXPERIMENTAL
Intervention: Music (135-140 beats per minute)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No music
Number of subjects: 20
Study: 35343933

Group type: EXPERIMENTAL
Intervention: Subparaneural upper trunk block (5 mL of 0.5% ropivacaine)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Interscalene block (15 mL of 0.5% ropivacaine)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Subparaneural upper trunk block
Number of subjects: 96

Group type: COMPARATOR
Intervention: Interscalene block
Number of subjects: 96
Study: 34195679

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 175

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 175